BofA lowered the firm’s price target on Silk Road Medical to $8 from $28 and keeps an Underperform rating on the shares. While the firm contends that current medtech multiples have “likely discounted too much for GLP-1 concerns,” unless expectations change on GLP-1 weight-loss drugs, medtech likely will trade at some discount compared to recent history and the firm lowering some targets in the group to reflect this new discount as well as higher interest rates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SILK:
- Piper sees finalized NCD as net negative for Silk Road, positive for InspireMD
- Silk Road Medical downgraded to Neutral from Buy at CL King
- Silk Road (NASDAQ:SILK) Plummets as Preliminary Q3 Revenues Disappoint
- Silk Road Medical downgraded to Sell from Buy at Citi
- Silk Road Medical downgraded to Neutral from Buy at B. Riley